Influence of rhG-CSF scheduling on megakaryocytopoietic recovery following 5-fluorouracil-induced hematotoxicity in splenectomized B6D2F1 mice

Stem Cells
S SchedingA Nakeff

Abstract

Recombinant human granulocyte colony-stimulating factor, rhG-CSF, is widely applied to ameliorate neutropenia following chemotherapy. However, rhG-CSF can exert negative effects on megakaryocytopoiesis that might cause a delay of megakaryocyte recovery. Therefore, the present study was designed to test different rhG-CSF administration protocols with regard to their megakaryocytic inhibitory potential in a 5-fluorouracil (5-FU)-induced experimental model system. Splenectomized B6D2F1 mice received a single injection of 5-FU (150 mg/kg) on day 0 followed by 50 micrograms/kg/day rhG-CSF given daily for either zero, four, or eight days. Five days after 5-FU, bone marrow and blood hematopoiesis were reduced significantly when compared with controls, independent of whether or not animals received rhG-CSF. However, nine days after 5-FU, granulopoietic recovery from 5-FU-induced toxicity was faster for rhG-CSF-treated versus untreated mice as demonstrated by higher values for colony forming unit-granulocyte macrophage (CFU-GM) and granulocytes (CFU-GM: 7.2 +/- 0.4 versus 5 +/- 0.6 x 10(4)/femur, granulocytes: 4.3 +/- 2 versus 1.4 +/- 0.4 x 10(5)/ml, respectively). Furthermore, significant mobilization of CFU-megakaryocyte (CFU-Meg) and...Continue Reading

References

Nov 1, 1979·British Journal of Haematology·J M Radley, G Scurfield
Mar 1, 1976·Proceedings of the Society for Experimental Biology and Medicine·A Nakeff, S Daniels-McQueen
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MorstynK Alton
Apr 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A M CohenL M Souza
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

❮ Previous
Next ❯

Citations

Nov 24, 2007·Regenerative Medicine·E ClarkeJ Damen
Oct 12, 2010·International Journal of Older People Nursing·Margaret O'Connor
Sep 28, 2005·Breast Cancer Research and Treatment·J N H Timmer-BonteV C G Tjan-Heijnen
Jun 14, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paola PapaldoFrancesco Cognetti
Oct 22, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Matthias HeilWolfgang Schaper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.